| scholarly article | Q13442814 |
| P2093 | author name string | Xing Zhang | |
| Jingjing Li | |||
| Jingjing Zhao | |||
| Wei Xiao | |||
| Yuanxiang Guan | |||
| Yao Liang | |||
| Bushu Xu | |||
| Yi Que | |||
| Ruiqing Peng | |||
| Xizhi Wen | |||
| P2860 | cites work | Translational research in diagnosis and management of soft tissue tumours | Q26748651 |
| PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells | Q28484680 | ||
| Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, | Q33393071 | ||
| Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group | Q33488674 | ||
| Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology | Q34677531 | ||
| The membrane-bound transcription factor CREB3L1 is activated in response to virus infection to inhibit proliferation of virus-infected cells. | Q35116452 | ||
| Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome | Q35673936 | ||
| Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group | Q36389207 | ||
| Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. | Q36473616 | ||
| Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers | Q36503782 | ||
| Staging soft tissue sarcoma: evolution and change. | Q36605717 | ||
| CREB3L1 is a metastasis suppressor that represses expression of genes regulating metastasis, invasion, and angiogenesis | Q37469514 | ||
| Cleavage of the membrane-bound transcription factor OASIS in response to endoplasmic reticulum stress | Q38316703 | ||
| Systemic Therapy for Advanced Soft Tissue Sarcoma | Q38829667 | ||
| miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 | ||
| Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity | Q39859811 | ||
| Treatment of adult rhabdomyosarcoma | Q43273367 | ||
| Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone | Q44320806 | ||
| Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. | Q51034282 | ||
| Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. | Q51714855 | ||
| Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group | Q68778289 | ||
| Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy | Q69226294 | ||
| Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system | Q71259989 | ||
| Ifosfamide, doxorubicin, vincristine, and etoposide in small cell lung cancer | Q72522339 | ||
| Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group | Q73862933 | ||
| ErbB-4 expression in limb soft-tissue sarcoma: correlation with the results of neoadjuvant chemotherapy | Q74387733 | ||
| Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide | Q77668222 | ||
| Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group | Q79338381 | ||
| Soft tissue sarcomas | Q79864313 | ||
| [Local recurrence in soft tissue sarcoma: prognostic factors] | Q82484622 | ||
| P433 | issue | 15 | |
| P304 | page(s) | 3517-3525 | |
| P577 | publication date | 2019-06-09 | |
| P1433 | published in | Journal of Cancer | Q6294901 |
| P1476 | title | Comparison of the MAID (AI) and CAV/IE regimens with the predictive value of cyclic AMP-responsive element-binding protein 3 like protein 1 (CREB3L1) in palliative chemotherapy for advanced soft-tissue sarcoma patients | |
| P478 | volume | 10 |
Search more.